newsfilter
← Latest News
PR Newswire·

Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer

Publication in Pharmaceuticals in May 2022 is titled Augmented Efficacy of Uttroside-B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma NEW YORK, July 26, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB:QBIO) a commercial-stage biotechnolo